Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The p53 tumor suppressor protein, found mutated in over 50% of all human tumors, is a sequence-specific
transcriptional activator
. Recent studies have identified a p53 relative, termed
p73
. We were interested in determining the relative abilities of wild-type and mutant forms of p53 and p73alpha and -beta isoforms to transactivate various p53-responsive promoters. We show that both p73alpha and p73beta activate the transcription of reporters containing a number of p53-responsive promoters in the p53-null cell line H1299. However, a number of significant differences were observed between p53 and
p73
and even between p73alpha and p73beta. Additionally, a Saccharomyces cerevisiae-based reporter assay revealed a broad array of transcriptional transactivation abilities by both
p73
isoforms at 37 degreesC. Recent data have shown that
p73
can associate with p53 by the yeast two-hybrid assay. When we examined complex formation in transfected mammalian cells, we found that p73alpha coprecipitates with mutant but not wild-type p53. Since many tumor-derived p53 mutants are capable of inhibiting transactivation by wild-type p53, we tested the effects of two representative hot-spot mutants (R175H and R248W) on
p73
. By cotransfecting p73alpha along with either p53 mutant and a p53-responsive reporter, we found that both R175H and R248W reduces the transcriptional activity of p73alpha. This decrease in transcriptional activity is correlated with the reduced ability of p73alpha to promote apoptosis in the presence of tumor-derived p53 mutants. Our data suggest the possibility that in some tumor cells, an outcome of the expression of mutant p53 protein may be to interfere with the endogenous
p73
protein.
...
PMID:p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. 989 Oct 77
Under normal conditions, tumor suppressor protein p53 exists in the cell in its latent form and is unable to function as a transcription factor. The allosteric model of p53 regulation postulates that the extreme portion of p53 carboxyl terminus (aa 364-393) binds to the core domain of the protein, thereby abrogating specific DNA binding in that region. In this study we propose an alternative mechanism of p53 functional regulation, which involves a separate molecule acting in trans to inhibit p53 transcriptional activity. Through the use of chimeric proteins of p53, p63gamma and p73beta, we show that the extreme COOH-terminal domain of p53 exerts a powerful and specific inhibitory effect on the
p73
- and p63-driven expression of a reporter gene. Moreover, fusion of p53 extreme COOH terminus to a completely unrelated
transcriptional activator
Gal4-VP16 also results in significant inhibition of transactivation activity. Since
p73
, p63, or Gal4-VP16 cannot associate with any part of the p53 molecule, we conclude that p53(aa 364-393) represses transcriptional activity of chimeric proteins and p53 itself through the binding of external negative modulator(s) in that region and not by the allosteric mechanism of regulation. In accordance with the "distinct inhibitor" hypothesis, the activity of wild type p53 is substantially increased by overexpression of chimeric proteins bearing p53(aa 364-393), which might be due to the competitive removal of transcriptional inhibitor(s). Our findings provide the basis for the identification of such negative modulators of p53 transcriptional activity.
...
PMID:Evidence for a distinct inhibitory factor in the regulation of p53 functional activity. 1138 62
p73
is a
transcriptional activator
related to tumor suppressor p53 and regulates differentiation, cell-cycle arrest, and apoptosis. Recently, zebrafish
p73
(zp73alpha) was isolated and shown to be required for zebrafish embryogenesis. In this study, we isolated a novel splicing-variant of zp73 mRNA, which was generated by the use of an alternative splicing acceptor site, and designated it as zp73theta;. The zp73theta; mRNA encoded a carboxy-terminal structure distinct from that of zp73alpha. Whereas the expression level of zp73theta; mRNA was much lower than that of zp73alpha in zebrafish adult tissues, it was relatively high and fluctuated during embryogenesis. Using Saos-2 cells for a transient reporter assay, we found that zp73theta;, but not zp73alpha, had strong transcriptional activity when the experiments were performed at 34 degrees C. In addition, zp73theta; had the ability to suppress the growth of Saos-2 cells and to cause the developmental defects in zebrafish. These data indicated that zp73theta; could work as a
transcriptional activator
in zebrafish.
...
PMID:Identification of a novel splicing form of zebrafish p73 having a strong transcriptional activity. 1554 66
The p53 tumor suppressor protein functions via specific gene activation to inhibit passage through the cell cycle and to trigger apoptosis. The p53 protein is homologous to p63 and
p73
, proteins that regulate transcription via the same promoter sequences but which activate different genes. In this study we tested whether p53, p63, and
p73
have different mechanisms of activating transcription and if such a difference could explain how each factor stimulates the transcription of distinct sets of genes. We found that when comparing p53 to the
transcriptional activator
, GAL4-VP16, both of which are classified as acidic activators, that stimulation of transcription by p53 is dependent upon low Mg2+ concentrations and limiting amounts of extract. By comparison, the stimulation of RNA synthesis by GAL4-VP16 was not dependent on a specific concentration of Mg2+ but did require higher amounts of extract, suggesting that a certain factor not required for p53-dependent gene activation was limiting in the extract. In contrast to the differences between p53 and GAL4-VP16, p63 and
p73
both regulated transcription in vitro under similar conditions as did p53. All three proteins, purified to near homogeneity, were equally active in binding to the p53-response element, and equally active in stimulating transcription reactions using naked DNA templates, DNA templates reconstituted in chromatin using histones purified from HeLa cells, or hyper-acetylated histones. These results argue that the gene specificity of p63 and
p73
dependent activation of transcription depends upon specific coactivators present in the specific cell types and upon other factors bound to the promoters.
...
PMID:The tumor suppressor protein p53 functions similarly to p63 and p73 in activating transcription in vitro. 1590 76
Human immunodeficiency virus type 1 (HIV-1) Tat is a potent
transcriptional activator
of the HIV-1 promoter and also has the ability to modulate a number of cellular regulatory circuits including apoptosis. Tat exerts its effects through interaction with viral as well as cellular proteins. Here, we studied the influence of
p73
, a protein that is implicated in apoptosis and cell cycle control, on Tat functions in the central nervous system. Protein interaction studies using immunoprecipitation followed by Western blot and glutathione S-transferase pull-down assays demonstrated the association of Tat with
p73
. Tat bound to the N-terminal region of
p73
spanning amino acids 1 to 120, and this interaction required the cysteine-rich domain (amino acids 30 to 40) of Tat. Association of
p73
with Tat prevented the acetylation of Tat on lysine 28 by PCAF. Functional studies including RNA interference showed that
p73
inhibited Tat stimulation of the HIV-1 promoter. Furthermore,
p73
prevented the interaction of Tat with cyclin T1 in vitro but not in vivo. These findings suggest possible new therapeutic approaches, using
p73
, for Tat-mediated AIDS pathogenesis.
...
PMID:p73 Interacts with human immunodeficiency virus type 1 Tat in astrocytic cells and prevents its acetylation on lysine 28. 1613 3
HIV-1 Tat is a potent
transcriptional activator
of the viral promoter with the ability to modulate a number of cellular regulatory circuits including apoptosis. Tat exerts its effects through interaction with viral as well as cellular proteins. Here, we studied the influence of
p73
, a protein that is implicated in apoptosis and cell cycle control, on Tat apoptotic function in the central nervous system. We recently demonstrated the ability of Tat to associate with
p73
, and that this association modulates Tat transcriptional activity (Amini et al., Mol Cell Biol 2005; 18: 8126-8138). We demonstrated that
p73
interferes with Tat-mediated apoptosis by preventing the up-regulation of Bax and down-regulation of Bcl-2 proteins in astrocytes. Thus, the interplay between Tat and
p73
may affect Tat contribution to apoptotic events in the brain, limiting its involvement in the neuropathology often observed in the brains of HIV-1 patients.
...
PMID:p73 modulates HIV-1 Tat transcriptional and apoptotic activities in human astrocytes. 1623 26
Zinc-finger protein 143 (ZNF143) is a human homolog of Xenopus
transcriptional activator
staf that is involved in selenocystyl tRNA transcription. We previously showed that ZNF143 expression is induced by treatment with DNA-damaging agents and that it preferentially binds to cisplatin-modified DNA. In this study, the potential function of ZNF143 was investigated. ZNF143 was overexpressed in cisplatin-resistant cells. ZNF143 knockdown in prostate cancer caused increased sensitivity for cisplatin, but not for oxaliplatin, etoposide and vincristine. We also showed that ZNF143 is associated with tumor suppressor gene product
p73
but not with p53.
p73
could stimulate the binding of ZNF143 to both ZNF143 binding site and cisplatin-modified DNA, and modulate the function of ZNF143. We provide a direct evidence that both Rad51 and flap endonuclease-1 are target genes of ZNF143 and overexpressed in cisplatin-resistant cells. Taken together, these experiments demonstrate that an interplay of ZNF143,
p73
and ZNF143 target genes is involved in DNA repair gene expression and cisplatin resistance.
...
PMID:ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. 1729 37
The expression of tumor suppressor
p73
is regulated at mRNA and protein levels. It has been shown that E2F1 acts as a
transcriptional activator
for
p73
. In this study, we have found that deregulated expression of E2F1 increases the mRNA level of
p73
, however, E2F1 promotes the degradation of
p73
. Immunoprecipitation experiments demonstrated that E2F1 forms a complex with
p73
and inhibits the transcriptional activity of
p73
. Enforced expression of E2F1 induces degradation of
p73
in a proteasome-independent manner. Additionally, the deletion analysis showed that E2F1(1-117) has an undetectable effect on
p73
, whereas E2F1(1-285) and E2F1(1-414) have an ability to promote degradation of
p73
and inhibition of
p73
transcriptional activity, suggesting that the region of E2F1 between amino acid residues 118 and 285 has a critical role in the regulation of
p73
. Taken together, our present study indicates that E2F1 has a dual role in the regulation of
p73
.
...
PMID:Deregulated expression of E2F1 promotes proteolytic degradation of tumor suppressor p73 and inhibits its transcriptional activity. 1957 72
EBV latent antigen EBNA3C is indispensible for in vitro B-cell immortalization resulting in continuously proliferating lymphoblastoid cell lines (LCLs). EBNA3C was previously shown to target pRb for ubiquitin-proteasome mediated degradation, which facilitates G1 to S transition controlled by the major
transcriptional activator
E2F1. E2F1 also plays a pivotal role in regulating DNA damage induced apoptosis through both p53-dependent and -independent pathways. In this study, we demonstrate that in response to DNA damage LCLs knocked down for EBNA3C undergo a drastic induction of apoptosis, as a possible consequence of both p53- and E2F1-mediated activities. Importantly, EBNA3C was previously shown to suppress p53-induced apoptosis. Now, we also show that EBNA3C efficiently blocks E2F1-mediated apoptosis, as well as its anti-proliferative effects in a p53-independent manner, in response to DNA damage. The N- and C-terminal domains of EBNA3C form a stable pRb independent complex with the N-terminal DNA-binding region of E2F1 responsible for inducing apoptosis. Mechanistically, we show that EBNA3C represses E2F1 transcriptional activity via blocking its DNA-binding activity at the responsive promoters of
p73
and Apaf-1 apoptosis induced genes, and also facilitates E2F1 degradation in an ubiquitin-proteasome dependent fashion. Moreover, in response to DNA damage, E2F1 knockdown LCLs exhibited a significant reduction in apoptosis with higher cell-viability. In the presence of normal mitogenic stimuli the growth rate of LCLs knockdown for E2F1 was markedly impaired; indicating that E2F1 plays a dual role in EBV positive cells and that active engagement of the EBNA3C-E2F1 complex is crucial for inhibition of DNA damage induced E2F1-mediated apoptosis. This study offers novel insights into our current understanding of EBV biology and enhances the potential for development of effective therapies against EBV associated B-cell lymphomas.
...
PMID:E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. 2243 5
Total and N-terminal isoform selective
p73
knockout mice show a variety of central nervous system defects. Here we show that TAp73 is a
transcriptional activator
of p75 neurotrophin receptor (p75(NTR)) and that p75(NTR) mRNA and protein levels are strongly reduced in the central and peripheral nervous systems of
p73
knockout mice. In parallel, primary cortical neurons from
p73
knockout mice showed a reduction in neurite outgrowth and in nerve growth factor-mediated neuronal differentiation, together with reduced miniature excitatory postsynaptic current frequencies and behavioral defects.
p73
null mice also have impairments in the peripheral nervous system with reduced thermal sensitivity, axon number, and myelin thickness. At least some of these morphological and functional impairments in
p73
null cells can be rescued by p75(NTR) re-expression. Together, these data demonstrate that loss of p75(NTR) contributes to the neurological phenotype of
p73
knockout mice.
...
PMID:TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. 2419 Sep 96
1